NAPU Napo Pharm Di

RNS Number:4921T
Napo Pharmaceuticals Inc
30 April 2008



For immediate release                                            30 April 2008


                            Napo Pharmaceuticals Inc.
                            ("Napo" or "the Company")
                                        
                        NAPO ANNUAL REPORT AND ACCOUNTS
                                        
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR
FROM THE UNITED STATES, AUSTRALIA,  CANADA OR JAPAN

South San Francisco, California, 30 April, 2008 - Napo Pharmaceuticals, Inc.,
(LSE: NAPL and NAPU), announces that its  Annual Report for the year ended 31
December 2007 will be posted on its website, www.napopharma.com, today by 5 pm 
California time. The document will also be made available for public inspection
at the UKLA's Document Viewing Facility.

An announcement will be made in due course upon posting of the document to the
Company's shareholders.

For more information please contract:

Napo Pharmaceuticals, Inc.
Lisa Conte, Chief Executive Officer
(001) + 650 616 1902

Charles Thompson, Chief Financial Officer
(001) + 650 616 1903

Buchanan Communications
(44) + 020 7466 5000
Tim Anderson, Mary-Jane Johnson

About Napo Pharmaceuticals, Inc.

Napo Pharmaceuticals, Inc. focuses on the development and commercialisation of
proprietary pharmaceuticals for the  global marketplace in collaboration with
local partners. Napo was founded in November 2001, and is based in California, 
USA with a subsidiary in Mumbai, India.

Napo's late-stage proprietary gastro-intestinal compound, crofelemer, is in
various stages of clinical development for  four distinct product indications,
including a late-stage Phase 3 program:

   CRO-HIV for AIDS diarrhoea, Phase 3
   CRO-IBS for diarrhoea irritable bowel syndrome ("D-IBS"), Phase 2
   CRO-ID for acute infectious diarrhoea (including cholera), Phase 2
   CRO-PED for paediatric diarrhoea, Phase 1

The FDA has granted fast-track status to CRO-IBS and CRO-HIV.

Crofelemer, a proprietary patented agent, is extracted from Croton lechleri, a
medicinal plant which can be sustainably  harvested from several countries in
South America. Napo also plans to develop an early clinical stage product, NP-
500,  for the treatment of insulin resistant diseases of Type II diabetes and
metabolic syndrome (Syndrome X; pre-diabetic  syndrome). Napo also has a plant
library of approximately 2,300 medicinal plants from tropical regions, and Napo
has  entered two screening relationship associated with this collection.

Currently, products are based on the chemical and biological diversity derived
from plants with medicinal properties,  but future products may be in-licensed
from other sources.

Napo has partnerships with Glenmark Pharmaceuticals Limited of India and
AsiaPharm Group Ltd. of China.

For more information please visit www.napopharma.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
ACSURVVRWSRSOAR

Napo Pharm Di (LSE:NAPU)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Napo Pharm Di (LSE:NAPU)
Historical Stock Chart
Von Jun 2023 bis Jun 2024